A new biomarker for Alzheimer’s disease may facilitate rapid diagnosis
Summary: The discovery of a unique ratio of metabolites in blood samples taken from patients with early-stage Alzheimer’s disease could provide a new key biomarker for the early detection of the neurodegenerative disease.
Source: Brain chemistry labs
Although the symptoms of advanced Alzheimer’s disease are well known, diagnosing Alzheimer’s disease in its early stages requires careful cognitive testing by neurologists.
The discovery of a unique ratio of metabolites from blood samples of patients with early-stage Alzheimer’s disease promises to speed up diagnosis, allowing earlier treatments to be initiated.
“We were delighted to find that the ratio of two molecules, 2-aminoethyl dihydrogen phosphate and taurine, allows us to reliably distinguish samples from early-stage Alzheimer’s disease patients from controls,” said Dr. Sandra Banack, lead author of the report in PLOS ONE and senior scientist at Brain Chemistry Labs in Jackson Hole.
The blood samples were taken from patients enrolled in an FDA-approved Phase II trial at Dartmouth Hitchcock Medical Center in New Hampshire and then shipped to brain chemistry labs for analysis.
Current attempts to diagnose Alzheimer’s disease from blood samples depend on the presence of amyloid fragments, the molecules that cause brain tangles and plaques.
“At Brain Chemistry Labs, we view amyloid plaques as a consequence rather than the cause of Alzheimer’s disease,” says Dr. Paul Alan Cox, Executive Director of Brain Chemistry Labs.
“What is exciting about this new finding is that it is not dependent on amyloid and the test can be performed on analytical equipment already present in most major hospitals.”
About this Alzheimer’s disease research news
Author: Marilyn Asay
Source: Brain chemistry labs
Contact: Marilyn Asay – Brain Chemistry Labs
Picture: Image is in public domain
Original research: Free access.
“A possible blood plasma biomarker for early-stage Alzheimer’s disease” by Sandra Banack et al. PLOS ONE
A possible blood plasma biomarker for early-stage Alzheimer’s disease
We sought to identify a usable biomarker from blood samples to characterize patients with early-stage Alzheimer’s disease (AD) to facilitate rapid diagnosis, early therapeutic intervention and clinical trial follow-up. .
We compared blood plasma metabolites from early-stage Alzheimer’s disease patients with blood plasma from healthy controls using two different analytical platforms: the amino acid analyzer and the tandem mass spectrometer.
Blood samples from patients with early-stage Alzheimer’s disease were obtained in an FDA-approved Phase IIa clinical trial (Clinicaltrial.gov NCT03062449). Participants included 25 patients with early-stage Alzheimer’s disease and 25 healthy controls in the United States.
We measured 2-aminoethyl dihydrogen phosphate and taurine concentrations in blood plasma samples.
We found that plasma concentrations of a phospholipid metabolite, 2-aminoethyl dihydrogen phosphate, normalized by taurine concentrations, distinguish blood samples from patients with early-stage AD.
This new potential biomarker of Alzheimer’s disease could complement clinical diagnosis for early detection of the disease.